Biogen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. 

CEO
Christopher A. Viehbacher
CEOChristopher A. Viehbacher
Employees
7,500
Employees7,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
1978
Founded1978
Employees
7,500
Employees7,500

BIIB Key Statistics

Market cap
28.17B
Market cap28.17B
Price-Earnings ratio
21.85
Price-Earnings ratio21.85
Dividend yield
Dividend yield
Average volume
1.52M
Average volume1.52M
High today
$192.60
High today$192.60
Low today
$189.96
Low today$189.96
Open price
$190.87
Open price$190.87
Volume
795.10K
Volume795.10K
52 Week high
$202.41
52 Week high$202.41
52 Week low
$110.04
52 Week low$110.04

Stock Snapshot

As of today, Biogen(BIIB) shares are valued at $192.03. The company's market cap stands at 28.17B, with a P/E ratio of 21.85.

As of 2026-02-21, Biogen(BIIB) stock has fluctuated between $189.96 and $192.60. The current price stands at $192.03, placing the stock +1.1% above today's low and -0.3% off the high.

The Biogen(BIIB)'s current trading volume is 795.1K, compared to an average daily volume of 1.52M.

During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.

During the past year, Biogen(BIIB) stock moved between $110.04 at its lowest and $202.41 at its peak.

BIIB News

Nasdaq 1d
First Week of BIIB October 16th Options Trading

Investors in Biogen Inc (Symbol: BIIB) saw new options begin trading this week, for the October 16th expiration. One of the key data points that goes into the p...

First Week of BIIB October 16th Options Trading
TipRanks 1d
Biogen’s BIIB091 MS Trial Reaches Completion, Setting Up a Key Pipeline Catalyst

Biogen Inc. (BIIB) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) is running a Phase 2 study called “A 2-Part, Multicenter, Randomized...

TipRanks 2d
Biogen initiated with an Equal Weight at Barclays

Barclays analyst Emily Field initiated coverage of Biogen (BIIB) with an Equal Weight rating and $185 price target The company is improving its pipeline and com...

Analyst ratings

53%

of 36 ratings
Buy
41.7%
Hold
52.8%
Sell
5.6%

More BIIB News

Simply Wall St 2d
Biogen Valuation Check After Earnings Momentum And Analyst Optimism

Biogen (BIIB) is back in focus after its latest quarterly earnings, where management highlighted contributions from newer drugs and analysts flagged the product...

Biogen Valuation Check After Earnings Momentum And Analyst Optimism

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.